Suppr超能文献

氧化钽纳米颗粒作为多功能高分辨率X射线造影剂用于乳腺癌啮齿动物模型的导管内图像引导消融手术。

Tantalum oxide nanoparticles as versatile and high-resolution X-ray contrast agent for intraductal image-guided ablative procedure in rodent models of breast cancer.

作者信息

Zaluzec Erin K, Kenyon Elizabeth, Volk Maximilian, Hayat Hasaan, Powell Katherine, Loomis Alexander, Chakravarty Shatadru, Hix Jeremy M L, Schipper Josh, Chang Chi, Kiupel Matti, Wang Ping, Shapiro Erik M, Sempere Lorenzo F

机构信息

Precision Health Program, Michigan State University, East Lansing, MI 48824, USA.

Department of Pharmacology & Toxicology, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA.

出版信息

Npj Imaging. 2024;2(1). doi: 10.1038/s44303-024-00007-5. Epub 2024 Feb 19.

Abstract

There are limited options for primary prevention of breast cancer (BC). Experimental procedures to locally prevent BC have shown therapeutic efficacy in animal models. To determine the suitability of FDA-approved iodine-containing and various metal-containing (bismuth, gold, iodine, or tantalum) preclinical nanoparticle-based contrast agents for image-guided intraductal (ID) ablative treatment of BC in rodent models, we performed a prospective longitudinal study to determine the imaging performance, local retention and systemic clearance, safety profile, and compatibility with ablative solution of each contrast agent. At least six abdominal mammary glands (>3 female FVB/JN mice and/or Sprague-Dawley rats, 10-11 weeks of age) were intraductally injected with commercially available contrast agents (Omnipaque 300, Fenestra VC, MVivoTM Au, MVivoTM BIS) or in-house synthesized tantalum oxide (TaOx) nanoparticles. Contrast agents were administered at stock concentration or diluted in 70% ethanol (EtOH) and up to 1% ethyl cellulose (EC) as gelling agent to assess their compatibility with our image-guided ablative procedure. Mammary glands were serially imaged by microCT for up to 60 days after ID delivery. Imaging data were analyzed by radiologists and deep learning to measure in vivo signal disappearance of contrast agents. Mammary glands and major organs were ultimately collected for histopathological examination. TaOx-containing solutions provided best imaging performance for nitid visualization of ductal tree immediately after infusion, low outward diffusion (<1 day) and high homogeneity. Of all nanoparticles, TaOx had the highest local clearance rate (46% signal decay as stock and 36% as ablative solution 3 days after ID injection) and exhibited low toxicity. TaOx-containing ablative solution with 1% EC caused same percentage of epithelial cell death (88.62% ± 7.70% vs. 76.38% ± 9.99%, value = 0.089) with similar minimal collateral damage (21.56 ± 5.28% vs. 21.50% ± 7.14%, value = 0.98) in mouse and rat mammary glands, respectively. In conclusion, TaOx-nanoparticles are a suitable and versatile contrast agent for intraductal imaging and image-guided ablative procedures in rodent models of BC with translational potential to humans.

摘要

乳腺癌(BC)的一级预防选择有限。在动物模型中,局部预防BC的实验方法已显示出治疗效果。为了确定美国食品药品监督管理局(FDA)批准的含碘和各种含金属(铋、金、碘或钽)的临床前纳米颗粒造影剂是否适用于啮齿动物模型中图像引导的导管内(ID)BC消融治疗,我们进行了一项前瞻性纵向研究,以确定每种造影剂的成像性能、局部滞留和全身清除、安全性以及与消融溶液的兼容性。向至少六个腹部乳腺(>3只10 - 11周龄的雌性FVB/JN小鼠和/或Sprague-Dawley大鼠)导管内注射市售造影剂(欧乃派克300、Fenestra VC、MVivoTM Au、MVivoTM BIS)或内部合成的氧化钽(TaOx)纳米颗粒。造影剂以原液浓度给药,或稀释于70%乙醇(EtOH)中,并加入高达1%的乙基纤维素(EC)作为胶凝剂,以评估它们与我们的图像引导消融程序的兼容性。在ID给药后长达60天内,通过微型计算机断层扫描(microCT)对乳腺进行连续成像。放射科医生和深度学习对成像数据进行分析,以测量造影剂在体内的信号消失情况。最终收集乳腺和主要器官进行组织病理学检查。含TaOx的溶液在注入后立即对导管树进行清晰可视化方面提供了最佳成像性能,向外扩散低(<1天)且均匀性高。在所有纳米颗粒中,TaOx具有最高的局部清除率(ID注射后3天,原液时信号衰减46%,消融溶液时为36%),且毒性低。含1% EC的TaOx消融溶液在小鼠和大鼠乳腺中分别导致相同比例的上皮细胞死亡(88.62% ± 7.70%对76.38% ± 9.99%,P值 = 0.089),且侧支损伤最小(分别为21.56 ± 5.28%对21.50% ± 7.14%,P值 = 0.98)。总之,TaOx纳米颗粒是一种适用于BC啮齿动物模型中导管内成像和图像引导消融程序的通用造影剂,具有向人类转化的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95a6/12118676/95ad2a5dc5d5/44303_2024_7_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验